Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
VE

NASDAQ · VERA

Vera Therapeutics, Inc.

Healthcare · Biotechnology

$35.05

Up+$1.45 (+4.32%)

Updated Sep 12, 2026, 11:06 AM

SID Score

4.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.94B
P/E ratio
-13.44
Dividend yield
0.00%
52-week range
$28.86 – $47.00
Volume
3.8M
Avg. volume
1.59M

Price performance

VERA price history

1M range · 20 trading sessions · Daily adjusted prices

VERA closed at $35.05 after 20 trading sessions, up 10.81% for the selected period.

Last close
$35.05
Period change
+10.81%
Period low
$31.26
Period high
$36.82
Daily close
View OHLC price history
VERA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$33.91$35.29$33.75$35.053.8M
Sep 10, 2026$33.49$34.29$32.88$33.602.03M
Sep 9, 2026$34.84$35.4829$33.75$33.78939.21K
Sep 8, 2026$35.80$35.995$34.885$35.281.44M
Sep 4, 2026$34.69$36.41$34.69$35.891.18M
Sep 3, 2026$35.53$35.74$34.53$34.99929.05K
Sep 2, 2026$34.44$35.73$33.8107$35.661.76M
Sep 1, 2026$33.73$34.40$33.65$34.234.07M
Aug 31, 2026$33.64$34.38$33.18$34.081.54M
Aug 28, 2026$34.40$34.47$33.34$34.191.26M
Aug 27, 2026$36.70$36.70$34.10$34.602.78M
Aug 26, 2026$35.10$36.96$34.6401$36.822.38M
Aug 25, 2026$34.05$35.57$34.00$35.282.49M
Aug 24, 2026$32.25$35.0917$32.02$33.722.41M
Aug 21, 2026$31.42$32.97$31.0331$32.2751.29M
Aug 20, 2026$32.295$32.295$30.72$31.261.56M
Aug 19, 2026$32.88$33.48$31.70$32.2751.26M
Aug 18, 2026$31.31$32.3499$31.31$32.281.03M
Aug 17, 2026$31.30$32.72$31.10$31.632.75M
Aug 14, 2026$31.29$32.31$29.73$31.635.88M

Latest VERA news

The latest Smart Investors Daily articles mentioning VERA.

Stock researchCompany · Overview

VERA research

Overview

Company profile and research snapshot.

Company profile

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.25
Implied upside
—
Analysts
—
VERA recent ratings
DateFirmRatingTarget
Sep 8, 2026JP MorganOverweight—
Aug 17, 2026WedbushNeutral—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 11, 2026WedbushNeutral—
Jul 8, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024

Yahoo · Sep 1, 2026

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=395559

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By